Results
Medpace Beats Q2 Estimates, Shares Jump 18.7%
Medpace reported Q2 adjusted EPS of $4.25, topping the $3.98 consensus, and revenue of $707.3 million, up 17.2% YoY.
EBITDA rose 17.6% to $153.4 million, yielding a 21.7% margin, while GAAP net income
